Management of Spironolactone-Induced Gynecomastia
Introduction to Alternative Treatments
- The American College of Cardiology recommends switching from spironolactone to eplerenone to eliminate gynecomastia while maintaining effective blood pressure control in elderly hypertensive patients 1
- Eplerenone was specifically designed with a 9,11-epoxide group to prevent binding to progesterone and androgen receptors, thereby avoiding gynecomastia and sexual dysfunction 1
Mechanism and Efficacy
- The European Society of Cardiology notes that spironolactone's non-selective binding to androgen and progesterone receptors causes anti-androgenic effects, leading to gynecomastia 2, 1
- Eplerenone provides equivalent efficacy for hypertension and resistant hypertension without the gynecomastia risk, as recommended by the American Heart Association 1
Treatment Guidelines
- The American Heart Association suggests starting eplerenone at an appropriate dose for hypertension (typically 50 mg once daily, may increase to 50 mg twice daily if needed) 1
- Note that eplerenone may require twice-daily dosing in some patients for adequate blood pressure control, according to the European Heart Journal 1
Alternative Therapies
- Amiloride (10-40 mg/day) can substitute for spironolactone in patients with gynecomastia, though it is more expensive and less effective than spironolactone metabolites, as reported in Hepatology 3